Precision BioSciences (DTIL) vs PepGen (PEPG)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Precision BioSciences (DTIL) has outperformed PepGen (PEPG) over the past year, gaining 12.8% versus a loss of 51.1%. Precision BioSciences is the larger company by market cap ($183.1 million vs $176.7 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | DTIL | PEPG |
|---|---|---|
| Share price | $6.63 | $2.56 |
| Market cap | $183.07M | $176.73M |
| 1-day change | +3.15% | +7.35% |
| YTD return | +54.57% | -63.44% |
| 1-year return | +12.81% | -51.13% |
| 5-year return | -97.81% | — |
| EPS (TTM) | $-1.35 | $-1.01 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $9.62 | $7.80 |
| 52-week low | $3.53 | $1.31 |
| Distance from 52-week high | -31.06% | -67.24% |
| Analyst consensus | none | none |
| Avg. price target upside | +343.27% | +298.83% |
| Average volume | 287.13K | 946.80K |
| Shares outstanding | 27.60M | 69.17M |
| Employees | 67 | 57 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- DTIL has outperformed PEPG by 63.9 percentage points over the past year.
About Precision BioSciences
DTIL stock →Precision BioSciences, Inc., a clinical stage gene editing company, develops in vivo gene editing therapies for gene edits, including gene insertion, excision, and elimination in the United States. The company offers ARCUS, a genome editing platform for DNA genome insertion, removal, and repair.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 67 employees
About PepGen
PEPG stock →PepGen Inc., a clinical-stage biotechnology company, develops oligonucleotide therapeutics for the treatment of severe neuromuscular and neurologic diseases in the United States. The company engages in the development of PGN-EDODM1, an EDO peptide-conjugated PMO, which is in Phase 2 clinical trial for the treatment of myotonic dystrophy type 1; and FREEDOM2-DM1, which is in Phase 2 for the treatment of myotonic dystrophy type 1.
Health Care · Biotechnology: Pharmaceutical Preparations · 57 employees
DTIL vs PEPG FAQ
Which is bigger, Precision BioSciences or PepGen?
Precision BioSciences (DTIL) is larger, with a market capitalization of $183.07M compared with $176.73M for PepGen (PEPG).
Which stock has performed better over the past year, DTIL or PEPG?
DTIL returned +12.81% over the past 12 months, compared with -51.13% for PEPG (price return, excluding dividends). Past performance does not predict future results.
Are Precision BioSciences and PepGen in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Biological Products (No Diagnostic Substances) for Precision BioSciences and Biotechnology: Pharmaceutical Preparations for PepGen.